Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24779791 | 1.00 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CHDAC4 | |
| SCHEMBL25894263 | 1.00 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CHDAC4 | |
| SCHEMBL12074843 | 0.87 | HDAC4 (0.47) | PNMTHTR2AHTR2BHTR2CHDAC4 | |
| SCHEMBL17149560 | 0.86 | PNMT (0.47) | PNMTHTR2AHTR2BHTR2CSLC6A4 | |
| SCHEMBL7929105 | 0.86 | PNMT (0.50) | PNMTHTR2AHTR2BHTR2CSLC6A4 | |
| SCHEMBL19656828 | 0.84 | PNMT (0.51) | PNMTHTR2AHTR2BHTR2CSLC6A4 | |
| SCHEMBL29949259 | 0.84 | PNMT (0.56) | PNMTHTR2AHTR2BHTR2CSLC6A4 | |
| SCHEMBL4617152 | 0.84 | PNMT (0.65) | PNMTHTR2AHTR2BHTR2CSLC6A4 | |
| SCHEMBL24779826 | 0.84 | PNMT (0.65) | PNMTHTR2AHTR2BHTR2CSLC6A4 | |
| SCHEMBL25853626 | 0.84 | PNMT (0.56) | PNMTHTR2AHTR2BHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| EP-3849968-B1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-03-04 | — | — | US | disclosed |
| US-20210040097-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3226858-B1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2021-02-03 | — | — | EP | disclosed |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10710995-B2 | Inhibitors of β-hydroxylase for treatment of cancer | RHODE ISLAND HOSPITAL (US) | 2020-07-14 | — | — | US | disclosed |
| US-8476621-B2 | Resin composition, gate insulating layer, and organic thin film transistor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-20110193071-A1 | RESIN COMPOSITION, GATE INSULATING LAYER, AND ORGANIC THIN FILM TRANSISTOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-11 | — | — | US | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | PNMT 842/4885HTR2A 1316/4885HTR2B 1129/4885 |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | PNMT 4829/4885HTR2A 1303/4885HTR2B 1154/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PNMT 107/4885HTR2A 14/4885HTR2B 18/4885 |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | PNMT 71/4885HTR2A 92/4885HTR2B 22/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | PNMT 1947/4885HTR2A 457/4885HTR2B 695/4885 |
| US-20210155604-A1 | QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF | EGFR, ERBB2, ERBB4 | PNMT 4081/4885HTR2A 1398/4885HTR2B 2418/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | PNMT 4670/4885HTR2A 360/4885HTR2B 421/4885 |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | PNMT 4001/4885HTR2A 2748/4885HTR2B 4308/4885 |
| US-10710995-B2 | Inhibitors of β-hydroxylase for treatment of cancer | ASPH, CYP46A1, AHR | PNMT 1010/4885HTR2A 2047/4885HTR2B 1602/4885 |
| US-20210040097-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | PNMT 1767/4885HTR2A 29/4885HTR2B 43/4885 |
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP4K2 | PNMT 2273/4885HTR2A 3429/4885HTR2B 3187/4885 |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | PNMT 4786/4885HTR2A 950/4885HTR2B 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.